Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Novartis to Acquire The Medicines Company at $85 a Share

November 25, 2019 0

Novartis to Acquire The Medicines Company Novartis (NVS) decided to buy The Medicines Company (MDCO) at …

An All Time High Market

November 23, 2019 0

Prohost Letter #437 An All Time High Market More Prohost Picks Have Reached the 2019 Targets …

Alnylam: Its Second RNAi Therapy Approval Boosted Savvy Investors’ Trust

November 22, 2019 0

Alnylam Granted FDA Early Approval of GIVLAARI™ for AHP Alnylam’s (ALNY) stock outperformed as its subcutaneous …

Why Vertex and CRISPR Rallied Today

November 19, 2019 0

Vertex Pharmaceuticals and CRISPR Therapeutics Rallied Today Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced positive, interim …

PTC Therapeutics’ Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

November 14, 2019 0

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics (PTCT) has positive results from part 2 of …

Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

November 13, 2019 0

Reata Pharmaceuticals CARDINAL Study Met Primary and Key Secondary Endpoints Reata Pharmaceuticals (RETA) announced that the …

Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

November 12, 2019 0

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis (EXEL) we learned that its …

Another Approval for Celgene and the First for Acceleron

November 12, 2019 0

FDA Approval for Celgene and Acceleron Drug REBLOZYL® The U.S. Food and Drug Administration (FDA) has …

What A Week For Biotechnology

November 11, 2019 0

The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

November 8, 2019 0

Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis (EXEL) and Daiichi Sankyo …

The Bad News That Might Save the Life of Halozyme Therapeutics

November 6, 2019 0

Halozyme Therapeutics is Focusing on ENHANZE® Technology Halozyme Therapeutics (HALO) decides to focus on its ENHANZE® …

Karyopharm Therapeutics: Is a Star Born?

November 6, 2019 0

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm …

The FDA Approves Compugen’s IND for Its Oncology Product COM902

November 4, 2019 0

Compugen FDA Approval for COM902 Compugen Announces FDA Clearance of IND Application for COM902 Phase 1 …

The Quarterly Financial Results

November 4, 2019 0

The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and …

IVERIC bio Stock Doubled and Continues to Outperform

November 1, 2019 0

IVERIC bio Stock Outperforms IVERIC bio (ISEE) has good news its stock is responding to. A …

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

October 31, 2019 0

Regenxbio Misleading Selloff A selloff of Regenxbio (RGNX) stock, following the FDA’s partial hold on the …

What Was Seen and What Was Ignored

October 29, 2019 0

The Week in Review #44 Quarterly Financial Results What Was Seen and What Was Ignored History …

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

October 24, 2019 0

Spring Bank Pharmaceuticals, Gilead Sciences and HBV If Spring Bank Pharmaceuticals’ (SBPH) product inarigivir in combination …

This Past Week

October 22, 2019 0

The Week in Review #43 This Past Week After hearing hints about the trade war between …

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

October 21, 2019 0

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics (SGEN) announced positive topline results from …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Novartis to Acquire The Medicines Company at $85 a Share

An All Time High Market

Alnylam: Its Second RNAi Therapy Approval Boosted Savvy Investors’ Trust

Why Vertex and CRISPR Rallied Today

PTC Therapeutics’ Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

Reata Pharmaceuticals: A Successful Treatment for Alport Syndrome

Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

Another Approval for Celgene and the First for Acceleron

What A Week For Biotechnology

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

The Bad News That Might Save the Life of Halozyme Therapeutics

Karyopharm Therapeutics: Is a Star Born?

The FDA Approves Compugen’s IND for Its Oncology Product COM902

The Quarterly Financial Results

IVERIC bio Stock Doubled and Continues to Outperform

When Negative Reactions to Biotechnology News Mislead. The Case of Regenxbio.

What Was Seen and What Was Ignored

Can the Combination of Inarigivir from Spring Bank Pharmaceuticals and Vemlidy from Gilead Sciences Succeed in Treating Chronic Hepatitis B Viral Infection

This Past Week

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target